Using MRI to Guide Neoadjuvant Chemotherapy for Breast Cancer
Posted: 05/22/2024 | By: Melissa E. Fryman, MS

Patients with stage II to III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. A study published by van der Voort et al in The Lancet Oncology investigated whether the duration of this chemotherapy could be tailored on the basis of radiological response.

Question 1 of 5

In the TRAIN-3 study, patients received neoadjuvant chemotherapy consisting of paclitaxel, trastuzumab, carboplatin, and pertuzumab intravenously. Patients were most frequently dosed with which agent(s), given on day 1 and day 8 of each cycle?

Choose 1